AIT Worldwide Logistics debuts new global headquarters in Chicago suburbs
14.8.2023 18:03:00 EEST | Business Wire | Press release
Corporate teammates for supply chain solutions leader AIT Worldwide Logistics recently moved into a new global headquarters at 2 Pierce Place in Itasca, Illinois. Previously, AIT’s shared services teams were based out of multiple Itasca facilities, including 701 Rohlwing Rd., a single-story building and warehouse that had been shared with the company’s Chicago station since 1997.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230814443050/en/
AIT’s new global headquarters occupies multiple floors of the iconic 25-story suburban tower at 2 Pierce Place in Itasca, Illinois. (Photo: Business Wire)
According to AIT’s Chairman and CEO, Vaughn Moore, the move was spurred by the organization’s exponential growth and emergence as a global logistics powerhouse.
“After more than 40 years in business, and immense expansion to more than 110 locations across Asia, Europe and North America, we’re fortifying our roots in the Chicago area,” Moore said. “This modern, highly visible location is a true manifestation of our global brand, and it provides our corporate staff with both the space and resources they need to best support our customers and teammates around the world.”
Moore added that the new location is a major investment in AIT teammates’ on-site work experience.
“Working together in this state-of-the-art office space allows us to be much more collaborative, enabling faster, real-time reactions,” he said. “2 Pierce Place also provides the additional space we need to accommodate the future growth of our shared services teams.”
AIT’s global headquarters occupies multiple floors of the iconic 25-story suburban tower. Standing at 395 feet, it is the second-tallest building in Illinois outside the Chicago city limits. From its modern lobby to the tenant lounge, game room and outdoor patio, 2 Pierce Place offers popular on-site amenities, including a fitness center, walking trail, a full-service deli serving breakfast and lunch, grab-and-go dining options, and on-site catering services.
Team members from accounting, claims, finance, global business systems, global compliance, human resources, imaging, information technology, legal and marketing are stationed on newly remodeled high-rise floors with conveniences including a private game room, coffee bars, sit-stand workstations, and multiple conference rooms equipped with state-of-the-art audio-visual capabilities.
In the coming months, the remaining Chicago area AIT teams in Itasca and Wood Dale (including dedicated food logistics and life sciences locations) are planning to move into a unified multi-service facility in the nearby suburb of Palatine. This new joint office and warehouse space is under construction. Meanwhile, AIT Truckload Solutions will continue to serve customers out of their current location at 55 W. Monroe St. in Chicago.
Conveniently located near the intersection of Interstate 290 and the Elgin-O’Hare Expressway, AIT’s new global headquarters is easily accessible from O’Hare International Airport:
|
AIT Worldwide Logistics |
|
2 Pierce Place, Suite 2100 |
|
Itasca, IL 60143 |
|
Tel: +1 (630) 766-8300 |
Learn more about 2 Pierce Place at twopierceplace.com.
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, food, government, healthcare, high-tech, industrial and life sciences. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes door-to-door deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 100 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814443050/en/
Contact information
Matt Sanders
Public Relations Manager
+1 (630) 766-8300
msanders@aitworldwide.com
AIT Worldwide Logistics, Inc.
Corporate Headquarters
701 N. Rohlwing Road
Itasca, IL 60143
800-669-4AIT (4248)
www.aitworldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
